About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Ibane Abasolo Olaortua Collaborators: Diego Baranda Martínez-Abasca, Miriam Izquierdo Sans Funding agency: Ministerio de Educación, Cultura y Deporte Funding: 59223.42 Reference: FPU20/04210 Duration: 01/12/2021 - 31/03/2025
IP: Ibane Abasolo Olaortua Collaborators: Marc Miquel Moltó Abad, Miriam Izquierdo Sans Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 90306.55 Reference: SLT017/20/000181 Duration: 05/07/2021 - 31/12/2024
IP: Maria Pilar Delgado Martínez Collaborators: Francesc Pujadas Navinés, Olga Maisterra Santos, Laura Castillo Ribelles, Carles Lorenzo Bosquet, Antonio Palasi Franco, Maria Belén Gutiérrez Iglesias, Jesús Pizarro Gonzálvez, Diana Liebana Gutierrez Funding agency: Instituto de Salud Carlos III Funding: 134310 Reference: PI19/00217 Duration: 01/01/2020 - 30/06/2024
IP: Marta Martínez Vicente Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies an, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Daniela Samaniego Toro, Laura Castillo Ribelles, Daniela Samaniego Toro Funding agency: Instituto de Salud Carlos III Funding: 245932.5 Reference: PI20/00728 Duration: 01/01/2021 - 30/06/2025
PMID: 38000766 Journal: JOURNAL OF BIOMEDICAL INFORMATICS Year: 2023 Reference: J Biomed Inform. 2023 Nov 22:104553. doi: 10.1016/j.jbi.2023.104553. Impact factor: Publication type: Paper in international publication Authors: Amasi-Hartoonian, Nare; Ammour, Nadir; Begum, Amina; Blanco, Albert; Brown, Mollie; Comas, Immaculada; Conesa, Laura; Couvert, Camille; Diaz-Troyano, Noelia; Didden, Eva-Maria et al. DOI: 10.1016/j.jbi.2023.104553
PMID: 38030066 Journal: Year: 2023 Reference: J Sport Health Sci. 2023 Nov 27:S2095-2546(23)00115-1. doi: 10.1016/j.jshs.2023.11.006. Impact factor: Publication type: Paper in international publication Authors: Alejo, Lidia B; Barranco-Gil, David; Bestard, Oriol; Bustos, Asuncion; Castellote-Belles, Laura; Couzi, Lionel; Fernandez-Ruiz, Mario; Ferrer-Costa, Roser; Kaminski, Hannah; Lucia, Alejandro et al. DOI: 10.1016/j.jshs.2023.11.006
PMID: 38036696 Journal: BJS Open Year: 2023 Reference: BJS Open. 2023 Nov 1;7(6):zrad106. doi: 10.1093/bjsopen/zrad106. Impact factor: Publication type: Paper in international publication Authors: Al-Sarrieh, Bilal A; Alejo, Lidia B; Alhaboob, Nassir; Aroori, Somaiah; Ausania, Fabio; Bari, Hassaan; Barranco-Gil, David; Bhogal, Ricky H; Bustos, Asuncion; Castellote-Belles, Laura et al. DOI: 10.1093/bjsopen/zrad106
PMID: 38068330 Journal: Journal of Clinical Medicine Year: 2023 Reference: J Clin Med. 2023 Nov 24;12(23):7276. doi: 10.3390/jcm12237276. Impact factor: Publication type: Paper in international publication Authors: Augustin, Salvador; Ferrer-Costa, Roser; Gabriel-Medina, Pablo; Guerrero, Rafael A; Jimenez-Masip, Alba; Marco, Andres; Munoz-Martinez, Sergio; On Behalf Of The Prisonafld Study Group Collaborators; Pericas, Juan M; Rivera-Esteban, Jesus et al. DOI: 10.3390/jcm12237276
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.
